SOPHiA GENETICS Reports Second Quarter 2026 Results

Impact · against what's priced in

SOPHiA GENETICS receives a positive catalyst from the first-ever companion diagnostic partnership with AstraZeneca and strong U.S. volume growth. AstraZeneca sees minimal impact as the partnership is a small-scale operational expansion relative to its size.

SOPH+0.70

No priced-in read yet

In context

The signing of two companion diagnostic programs with AstraZeneca marks a first for the company and validates its AI platform, while 27% revenue growth and 60% U.S. volume growth demonstrate strong scaling.

Read from the article alone

• healthcare techNew
• earnings
• ai
• AZN
• SOPH
• biopharma
• diagnostics
• liquid biopsy
• precision medicine